TY - JOUR
T1 - Biophysical activity of animal-derived exogenous surfactants mixed with rifampicin
AU - Kolomaznik, M.
AU - Calkovska, A.
AU - Herting, E.
AU - Stichtenoth, G.
N1 - Publisher Copyright:
© 2014, Springer International Publishing Switzerland
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2015/9/25
Y1 - 2015/9/25
N2 - Exogenous pulmonary surfactant is a potential delivery system for topical medications via the conducting airways. Due to the sensitivity to inactivation of surfactant, mutual interaction with the shipped drug should be evaluated. Little is known about the interactions between surfactant and antimicrobial drugs. The aim of the present study was to evaluate whether biophysical properties of animal-derived surfactants are modified by the bactericidal antibiotic rifampicin. An intracellular activity and a broad antimicrobiotic spectrum toward Gram-negative and Gram-positive bacteria make rifampicin an interesting substance against pulmonary infections. Curosurf® (porcine surfactant from minced lungs) and Survanta® (bovine surfactant extract) were diluted to 2.5–5.0 mg/ml of phospholipids in 0.9 % NaCl and rifampicin (RIF) was added at 1, 5, and 10 % (w/w). Minimum (γmin) and maximum (γmax) surface tension of a cyclically compressed bubble in the mixture was assessed with a pulsating bubble surfactometer. After 5 min, γmin of Survanta at a concentration of 3 mg/ml was significantly increased after addition of 5 and 10% RIF (both p < 0.001). At 1 % RIF, the γmin of Survanta was 10 mN/m and this value was not significantly different to that of Survanta alone. The γmin of Curosurf at 3 mg/ml was increased with 10 % RIF (p < 0.001), but not with 1 and 5 %. At 5 mg/ml Survanta was inhibited by 10 % RIF (p < 0.05), while γmin of Curosurf was low (<5 mN/m) in all mixtures. In conclusion, Curosurf and Survanta interfere with RIF in a concentration-dependent manner. At the appropriate phospholipid concentration, especially porcine-derived surfactant is able to retain good surface activity when mixed with antibiotics.
AB - Exogenous pulmonary surfactant is a potential delivery system for topical medications via the conducting airways. Due to the sensitivity to inactivation of surfactant, mutual interaction with the shipped drug should be evaluated. Little is known about the interactions between surfactant and antimicrobial drugs. The aim of the present study was to evaluate whether biophysical properties of animal-derived surfactants are modified by the bactericidal antibiotic rifampicin. An intracellular activity and a broad antimicrobiotic spectrum toward Gram-negative and Gram-positive bacteria make rifampicin an interesting substance against pulmonary infections. Curosurf® (porcine surfactant from minced lungs) and Survanta® (bovine surfactant extract) were diluted to 2.5–5.0 mg/ml of phospholipids in 0.9 % NaCl and rifampicin (RIF) was added at 1, 5, and 10 % (w/w). Minimum (γmin) and maximum (γmax) surface tension of a cyclically compressed bubble in the mixture was assessed with a pulsating bubble surfactometer. After 5 min, γmin of Survanta at a concentration of 3 mg/ml was significantly increased after addition of 5 and 10% RIF (both p < 0.001). At 1 % RIF, the γmin of Survanta was 10 mN/m and this value was not significantly different to that of Survanta alone. The γmin of Curosurf at 3 mg/ml was increased with 10 % RIF (p < 0.001), but not with 1 and 5 %. At 5 mg/ml Survanta was inhibited by 10 % RIF (p < 0.05), while γmin of Curosurf was low (<5 mN/m) in all mixtures. In conclusion, Curosurf and Survanta interfere with RIF in a concentration-dependent manner. At the appropriate phospholipid concentration, especially porcine-derived surfactant is able to retain good surface activity when mixed with antibiotics.
UR - http://www.scopus.com/inward/record.url?scp=84925023175&partnerID=8YFLogxK
U2 - 10.1007/5584_2014_64
DO - 10.1007/5584_2014_64
M3 - Journal articles
C2 - 25252905
AN - SCOPUS:84925023175
SN - 0065-2598
VL - 839
SP - 31
EP - 39
JO - Advances in experimental medicine and biology
JF - Advances in experimental medicine and biology
ER -